Department of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Yunnan Institute of Experimental Diagnosis, Kunming, China.
PLoS One. 2018 Oct 4;13(10):e0203155. doi: 10.1371/journal.pone.0203155. eCollection 2018.
Aberrant DNA methylation occurs frequently in cancer. The aim of this study was to identify novel methylation markers in lung cancer in Xuanwei, China, through integrated genome-wide DNA methylation and gene expression studies.
Differentially methylated regions (DMRs) and differentially expressed genes (DEGs) were detected on 10 paired lung cancer tissues and noncancerous lung tissues by methylated DNA immunoprecipitation combined with microarray (MeDIP-chip) and gene expression microarray analyses, respectively. Integrated analysis of DMRs and DEGs was performed to screen out candidate methylation-related genes. Both methylation and expression changes of the candidate genes were further validated and analyzed.
Compared with normal lung tissues, lung cancer tissues expressed a total of 6,899 DMRs, including 5,788 hypermethylated regions and 1,111 hypomethylated regions. Integrated analysis of DMRs and DEGs identified 45 tumor-specific candidate genes: 38 genes whose DMRs were hypermethylated and expression was downregulated, and 7 genes whose DMRs were hypomethylated and expression was upregulated. The methylation and expression validation results identified 4 candidate genes (STXBP6, BCL6B, FZD10, and HSPB6) that were significantly hypermethylated and downregulated in most of the tumor tissues compared with the noncancerous lung tissues.
This integrated analysis of genome-wide DNA methylation and gene expression in lung cancer in Xuanwei revealed several genes regulated by promoter methylation that have not been described in lung cancer before. These results provide new insight into the carcinogenesis of lung cancer in Xuanwei and represent promising new diagnostic and therapeutic targets.
异常的 DNA 甲基化在癌症中经常发生。本研究旨在通过全基因组 DNA 甲基化和基因表达综合研究,在中国宣威鉴定肺癌中的新型甲基化标志物。
通过甲基化 DNA 免疫沉淀联合微阵列(MeDIP-chip)和基因表达微阵列分析,分别在 10 对肺癌组织和非癌性肺组织中检测差异甲基化区域(DMR)和差异表达基因(DEG)。对 DMR 和 DEG 进行综合分析,筛选候选甲基化相关基因。进一步验证和分析候选基因的甲基化和表达变化。
与正常肺组织相比,肺癌组织共表达 6899 个 DMR,包括 5788 个高甲基化区域和 1111 个低甲基化区域。DMR 和 DEG 的综合分析鉴定出 45 个肿瘤特异性候选基因:38 个基因的 DMR 呈高甲基化且表达下调,7 个基因的 DMR 呈低甲基化且表达上调。对候选基因的甲基化和表达验证结果表明,4 个候选基因(STXBP6、BCL6B、FZD10 和 HSPB6)在大多数肿瘤组织中明显高甲基化且表达下调,与非癌性肺组织相比。
本研究通过全基因组 DNA 甲基化和基因表达的综合分析,揭示了一些以前在肺癌中未描述的受启动子甲基化调控的基因。这些结果为宣威肺癌的致癌机制提供了新的见解,并代表了有前途的新的诊断和治疗靶点。